Vir Biotechnology (NASDAQ:VIR) Director Sells $209,220.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $9.51, for a total transaction of $209,220.00. Following the sale, the director owned 1,122,391 shares of the company’s stock, valued at approximately $10,673,938.41. This represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $9.10 on Friday. The stock’s 50-day moving average is $7.27 and its 200 day moving average is $6.20. The company has a market cap of $1.27 billion, a PE ratio of -2.88 and a beta of 1.65. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company had revenue of $64.07 million during the quarter, compared to analyst estimates of $19.91 million. During the same quarter last year, the firm posted ($0.76) earnings per share. The firm’s revenue was up 417.8% on a year-over-year basis. Analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on VIR shares. Needham & Company LLC lifted their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. HC Wainwright lifted their price target on Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective for the company in a report on Tuesday, February 24th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $20.44.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARCH Venture Management LLC bought a new stake in shares of Vir Biotechnology in the 2nd quarter worth $65,100,000. GSK plc purchased a new stake in shares of Vir Biotechnology during the fourth quarter valued at $51,562,000. State Street Corp increased its holdings in Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after buying an additional 988,262 shares in the last quarter. Orbimed Advisors LLC increased its holdings in Vir Biotechnology by 5.9% in the 2nd quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after buying an additional 132,466 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Vir Biotechnology by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock worth $14,041,000 after buying an additional 81,985 shares during the last quarter. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.